NDA 209531 · Biogen
Spinraza
Nusinersen Sodium · Intrathecal · Survival Motor Neuron-2-directed RNA Interaction; Antisense Oligonucleotide
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Mar 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2016
Dec 23, 2016
Approved uses
4
Original approval plus efficacy supplements
Registered trials
23
8 Phase 3, 4 recruiting
FAERS reports
7,888
3,872 serious, 798 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 31, 2026.
SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. SPINRAZA is a survival motor neuron-2 (SMN2)-directed antisense oligonucleotide indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients ( 1 )
Mechanism: SPINRAZA is an antisense oligonucleotide (ASO) designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Using in vitro assays and studies in transgenic animal models of SMA, SPINRAZA was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts and production of full-length SMN protein.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 27, 2026 Supplement 16 · Efficacy OrphanLabelLetter
- Jun 16, 2020 Supplement 10 · Efficacy OrphanLetterLabel
- May 14, 2018 Supplement 3 · Efficacy OrphanLetterLabel
- Dec 23, 2016 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
3 products under this application
- SPINRAZA · NUSINERSEN SODIUM EQ 50MG BASE/5ML (EQ 10MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
- SPINRAZA · NUSINERSEN SODIUM EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
- SPINRAZA · NUSINERSEN SODIUM EQ 28MG BASE/5ML (EQ 5.6MG BASE/ML) · SOLUTION, INTRATHECAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Nusinersen" as an intervention, any sponsor and status, largest first.
- A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational StudiesPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02594124 · 292 participants · Start Nov 4, 2015 · Primary completion Aug 21, 2023
Drug: nusinersen · For: Spinal Muscular Atrophy
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 47 sites in all
- Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or RisdiplamPivotal-lookingCompleted
Scholar Rock, Inc.Industry
NCT05156320 · 188 participants · Start Apr 14, 2022 · Primary completion Dec 18, 2024
Drug: Apitegromab; Placebo · For: Spinal Muscular Atrophy; Spinal Muscular Atrophy Type 3; Spinal Muscular Atrophy Type 2 and 7 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Los Angeles, California · 50 sites in all
- Study of Nusinersen (BIIB058) in Participants With Spinal Muscular AtrophyPivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT04089566 · 145 participants · Start Mar 26, 2020 · Primary completion Feb 21, 2024
Drug: Nusinersen · For: Muscular Atrophy, Spinal
Sites: Palo Alto, California; Aurora, Colorado; Chicago, Illinois · 45 sites in all
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Participants With Later-onset Spinal Muscular Atrophy (SMA)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT02292537 · 126 participants · Start Nov 24, 2014 · Primary completion Feb 20, 2017
Drug: Nusinersen · For: Spinal Muscular Atrophy
Sites: Los Angeles, California; Palo Alto, California; Aurora, Colorado · 24 sites in all
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular AtrophyPivotal-lookingTerminated
BiogenBiogen (BIIB)
NCT02193074 · 122 participants · Start Aug 19, 2014 · Primary completion Nov 21, 2016
Drug: nusinersen · For: Spinal Muscular Atrophy
Sites: Los Angeles, California; Aurora, Colorado; Orlando, Florida · 31 sites in all
- A Study to Learn About the Long-Term Safety of Higher Doses of Nusinersen (BIIB058) Given as Injections to Participants With Spinal Muscular Atrophy (SMA) Who Took Part in an Earlier Nusinersen Trial (ONWARD)Pivotal-lookingCompleted
BiogenBiogen (BIIB)
NCT04729907 · 115 participants · Start Apr 19, 2021 · Primary completion Jul 30, 2026
Drug: Nusinersen · For: Muscular Atrophy, Spinal
Sites: Sacramento, California; Aurora, Colorado; Chicago, Illinois · 39 sites in all
BiogenBiogen (BIIB)
NCT06555419 · 78 participants (planned) · Start Jan 16, 2025 · Primary completion Sep 30, 2027
Drug: Nusinersen · For: Muscular Atrophy, Spinal
Sites: Phoenix, Arizona; Orange, California; Palo Alto, California · 21 sites in all
Hospices Civils de LyonAcademic, hospital or other
NCT06321965 · 60 participants (planned) · Start Jul 24, 2024 · Primary completion Jan 24, 2029
Drug: Biocollection · For: Spinal Muscular Atrophy
Sites: Bron, France; Brest, France; Garche, France · 8 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache578
- post lumbar puncture syndrome524
- pyrexia410
- procedural pain386
- pneumonia371
- death339
- vomiting315
- asthenia302
- back pain265
- fatigue253
- scoliosis230
- fall186
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 1 |
| 2017 | 637 |
| 2018 | 1,223 |
| 2019 | 945 |
| 2020 | 800 |
| 2021 | 958 |
| 2022 | 801 |
| 2023 | 729 |
| 2024 | 624 |
| 2025 | 594 |
| 2026 | 576 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Spinraza (Nusinersen Sodium/PF)
2024 spending
$3.4M
Beneficiaries
n/a
24 claims
Per beneficiary
n/a
$28,221.54 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $5,622,217 |
| 2021 | $2,782,478 |
| 2022 | $2,632,872 |
| 2023 | $3,116,508 |
| 2024 | $3,386,585 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.
Finkel RS, Mercuri E, Darras BT, et al. · N Engl J Med 2017 · Clinical Trial, Phase III, Multicenter Study
- Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial.
Crawford TO, Servais L, Mercuri E, et al. · Lancet Neurol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
Mercuri E, Darras BT, Chiriboga CA, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Comparative Study
- An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies.
Giess D, Erdos J, Wild C · Eur J Paediatr Neurol 2024 · Systematic Review
- Absorption, Distribution, Metabolism, and Excretion of US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
Migliorati JM, Liu S, Liu A, et al. · Drug Metab Dispos 2022 · Meta-Analysis, Review
- High-dose nusinersen for spinal muscular atrophy: a phase 3 randomized trial.
Finkel RS, Crawford TO, Mercuri E, et al. · Nat Med 2026 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Biogen
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.